AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37266993
Drug: High-dose corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose corticosteroids
Trial: 33452923
Drug: 6‐mg dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6‐mg dexamethasone (4 × 6‐mg)
Trial: 33452923
Drug: 12‐mg dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12‐mg dexamethasone (2 × 12‐mg)
Trial: 32961542
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg memantine
Trial: 33136047
Drug: 50 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 Gy radiation dose (1 fractioned dose of 2 Gy per day, 5 days per week, for 5 weeks)
Trial: 33136047
Drug: 70 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 Gy radiation dose (1 fractioned dose of 2 Gy per day, 5 days per week, for 7 weeks)
Trial: 33136047
Drug: 50 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 Gy radiation dose
Trial: 33136047
Drug: 70 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 Gy radiation dose
Trial: 35293068
Drug: Oleoylethanolamide (OEA)
RxNorm normalized name: Palmitoylethanolamide
DrugBank: Oleic monoethanolamide (DB16495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oleoylethanolamide (OEA) 125 mg per day for 2 months
Trial: 39060905
Drug: Tumor necrosis
RxNorm normalized name: Tumor necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor necrosis factor inhibitors (TNFi)
Trial: 39300794
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg every 2 weeks
Trial: 36958470
Drug: Dupilumab 200
RxNorm normalized name: dupilumab 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 200 mg every 2 weeks
Trial: 33058901
Drug: Computer VR-agent
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Computer VR-agent exclusion
Trial: 32651467
Drug: Nivolumab (anti-PD-1)
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab (anti-PD-1) administered every two weeks for four cycles (two cycles prior to first HDR, two cycles prior to second HDR) combined with androgen deprivation therapy (ADT) and high-dose-rate (HDR) brachytherapy.
Trial: 32911988
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D (600 IU/day plus 50,000 IU/week)
Trial: 32911988
Drug: Low-dose vitamin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vitamin D (600 IU/day plus placebo weekly)
Trial: 32621898
Drug: Capsule tension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule tension ring (in PEX group)
Trial: 32621898
Drug: No capsule
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No capsule tension ring (in PEX group)
Trial: 32504574
Drug: Dolutegravir 50
RxNorm normalized name: dolutegravir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg, abacavir 600 mg, and lamivudine 300 mg
Trial: 37429432
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion
Trial: 35895381
Drug: Nivolumab (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (360 mg) + gemcitabine and cisplatin (days 1 and 8 every 3 weeks for 6 months) followed by nivolumab (240 mg every 2 weeks)
Trial: 35578360
Drug: Dalbavancin (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalbavancin (two doses on days 1 and 8)
Trial: 35578360
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous antibiotic therapy (4–8 weeks)
Trial: 35332558
Drug: Inebilizumab 300
RxNorm normalized name: INEBILIZUMAB
DrugBank: Inebilizumab (DB12530)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inebilizumab 300 mg intravenous dose administered on Day 1 and Day 15 and every 6 months thereafter
Trial: 33735712
Drug: Lopinavir/Ritonavir (800/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/Ritonavir (800/200 mg daily)
Trial: 34482574
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of omega-3 fatty acids (300 mg daily) and vitamin D3 (50,000 IU weekly)
Trial: 34482574
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids supplementation (300 mg daily)
Trial: 32334551
Drug: 42.5 g
RxNorm normalized name: PETROLATUM 57.3 g in 100 g / MINERAL OIL 42.5 g in 100 g OPHTHALMIC OINTMENT [MOISTU-EYES]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 42.5 g of almonds per day
Trial: 32400122
Drug: Antiplatelet/Anticoagulant therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet/Anticoagulant therapy
Trial: 32400122
Drug: Antiplatelet/Anticoagulant therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet/Anticoagulant therapy in lowest platelet quartile
Trial: 33087047
Drug: IVIg (human)
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IVIg (human) - four vials daily for 3 days
Trial: 38717556
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers
Trial: 33210444
Drug: Salmeterol 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 400 μg
Trial: 33891194
Drug: Eribulin (1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin (1.4 mg/m2 on day one and eight of each 21-day cycle)
Trial: 33891194
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of physician’s choice (TPC) including paclitaxel, docetaxel, nab-paclitaxel or vinorelbine
Trial: 33891194
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of physician’s choice (TPC)
Trial: 32857051
Drug: Curry solution
RxNorm normalized name: CURRY RED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curry solution (distilled water with curry powder containing turmeric)
Trial: 33145841
Drug: TAS-303 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-303 (3 mg and 6 mg)
Trial: 35758017
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (NaHCO3) 0.3 g/kg body mass
Trial: 35105570
Drug: Colchicine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (0.5 mg daily for 3 days before surgery and 0.5 mg daily for 5 days after surgery)
Trial: 33689854
Drug: Radical radiation
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical radiation therapy with carbogen (98% O2; 2% CO2) and nicotinamide (CON)
Trial: 33689854
Drug: Radical radiation
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical radiation therapy alone (RT)
Trial: 33689854
Drug: Radical radiation
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical radiation therapy with CON in patients with tumor necrosis
Trial: 33689854
Drug: Radical radiation
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical radiation therapy with CON in patients with high hypoxia gene score
Trial: 32473817
Drug: Overall performance
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall performance of treatment centers
Trial: 32441302
Drug: Costoclavicular approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Costoclavicular approach (CC) with modified double-injection technique
Trial: 32441302
Drug: Supraclavicular approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supraclavicular approach (SC) with modified double-injection technique
Trial: 36451509
Drug: Conventional intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intradermal acupuncture
Trial: 33624081
Drug: Boosted protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boosted protease inhibitor (bPI) plus lamivudine dual therapy
Trial: 33624081
Drug: Boosted protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boosted protease inhibitor (bPI) monotherapy
Trial: 33624081
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (bPI + lamivudine)
Trial: 34027782
Drug: Foley’s‐misoprostol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foley’s‐misoprostol (25 µg vaginal misoprostol tablet)
Trial: 34013839
Drug: L-Citrulline supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Citrulline supplementation
Trial: 35699910
Drug: Dapagliflozin (SGLT2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (SGLT2 inhibitor)
Trial: 33260196
Drug: Yoga intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga intervention (daily sessions for one week)
Trial: 34019729
Drug: DGC-CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DGC-CC
Trial: 33546020
Drug: Shenfu injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu injection combined with furosemide
Trial: 34719869
Drug: ADEB (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADEB (standard chemotherapy plus bortezomib)
Trial: 34719869
Drug: ADE (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADE (standard chemotherapy without bortezomib)
Trial: 36284289
Drug: Depth of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depth of anesthesia set to BIS 45 (group L)
Trial: 33725323
Drug: Rivaroxaban (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (2.5 mg twice daily) plus Aspirin (100 mg once daily)
Trial: 38320511
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg once daily)
Trial: 36115497
Drug: Inhaled treprostinil
RxNorm normalized name: treprostinil Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled treprostinil (high dose, ≥9 breaths per session)
Trial: 36115497
Drug: Inhaled treprostinil
RxNorm normalized name: treprostinil Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled treprostinil (low dose, <9 breaths per session)
Trial: 36115497
Drug: Placebo (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (high dose)
Trial: 36115497
Drug: Placebo (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (low dose)
Trial: 35436940
Drug: Acetaminophen (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1000 mg)
Trial: 38290758
Drug: Conventional colonoscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional colonoscopy (CC)
Trial: 33855080
Drug: Control (fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (fixed dose of 1000 mL crystalloid fluid)
Trial: 34906619
Drug: Mandibular single-implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular single-implant overdentures (1-IODs)
Trial: 32527501
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg kg−1 methylprednisolone in 5 mL of saline
Trial: 32527501
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of saline (Control Group)
Trial: 35027153
Drug: Interpersonal-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal-focused therapy
Trial: 33104519
Drug: Rg1 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rg1 (5 mg, an immunostimulant ginsenoside)
Trial: 35365305
Drug: STEP‐KOA (internet‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STEP‐KOA (internet‐based exercise training program, phone counseling, physical therapy)
Trial: 33678513
Drug: Edasalonexent 67
RxNorm normalized name: Edasalonexent
DrugBank: Edasalonexent (DB15010)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edasalonexent 67 mg/kg/day
Trial: 33678513
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or off-treatment control
Trial: 34941114
Drug: Nebulized enriched
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized enriched heparin (2.5 mg/mL 0.9% saline)
Trial: 35817323
Drug: 40 Gy/15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 Gy/15 fractions/3 weeks (standard treatment)
Trial: 35817323
Drug: 26 Gy/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 26 Gy/5 fractions/1 week (novel treatment)
Trial: 35817323
Drug: 12 Gy/4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 Gy/4 fractions/4 days (sequential boost)
Trial: 36231152
Drug: Ashwagandha (ASH)
RxNorm normalized name: ASH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ashwagandha (ASH) 400 mg
Trial: 35156040
Drug: Therapist‐assisted cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist‐assisted cognitive behavioral therapy for insomnia
Trial: 34085549
Drug: Intravenous dexketoprofen
RxNorm normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexketoprofen
Trial: 34762528
Drug: Bosentan (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (125 mg twice a day for 3 days)
Trial: 34194732
Drug: 2.5% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% chlorhexidine solution and 0.9% NaCl
Trial: 32805205
Drug: 12 μg
RxNorm normalized name: penicillin G 12 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 μg lubiprostone
Trial: 33295809
Drug: Lorazepam (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (0.05 mg/kg bolus followed by 4-h normal saline infusion)
Trial: 32726499
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS 30 mg administered in the morning (N-M)
Trial: 32726499
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS 30 mg administered at night (N-N)
Trial: 32726499
Drug: Amlodipine besylate
RxNorm normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine besylate 5 mg administered in the morning (A-M)
Trial: 32726499
Drug: Amlodipine besylate
RxNorm normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine besylate 5 mg administered at night (A-N)
Trial: 34507102
Drug: CDP-choline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP-choline (2 g/day for 8 weeks)
Trial: 36286885
Drug: Dietressa (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietressa (6 tablets per day for 24 weeks)
Trial: 33301386
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (normal daily routine)
Trial: 33428746
Drug: CrashCourse (CC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CrashCourse (CC)
Trial: 35212274
Drug: GSMs-TACE plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSMs-TACE plus synchronous antigen-presenting dendritic cell (DC) sequential reinfusion
Trial: 36151584
Drug: Perinatal Emotional
RxNorm normalized name: PERINEAL WASH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perinatal Emotional Skills Groups (ESGs) + Treatment as Usual (TAU)
Trial: 34802026
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid (tTXA) 1g (20mL) soaked in absorbable gelatin sponge
Trial: 34802026
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid (tTXA)
Trial: 32701903
Drug: Sitagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (100 mg/d)
Trial: 32215767
Drug: Debridement and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debridement and laser treatment
Trial: 33753147
Drug: Baicalein tablets
RxNorm normalized name: Baicalein
DrugBank: Baicalein (DB16101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baicalein tablets (200 mg, 400 mg, 600 mg, or 800 mg)
Trial: 33753147
Drug: Baicalein tablets
RxNorm normalized name: Baicalein
DrugBank: Baicalein (DB16101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baicalein tablets (400 mg)
Trial: 33753147
Drug: Baicalein tablets
RxNorm normalized name: Baicalein
DrugBank: Baicalein (DB16101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baicalein tablets (600 mg)
Trial: 36969889
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg TDF
Trial: 33789011
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg upadacitinib
Trial: 33789011
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg upadacitinib vs. Adalimumab
Trial: 34727201
Drug: L-carnitine 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine 1000 mg/day
Trial: 34859631
Drug: Routine outpatient
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine outpatient treatment
Trial: 36494006
Drug: Chemotherapy (investigator's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (investigator's choice of paclitaxel, docetaxel, or vinflunine)
Trial: 83012907
Drug: Methadone 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone 20 mg
Trial: 35676012
Drug: Biodegradable polymer
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biodegradable polymer drug-eluting stents (BP-DES)
Trial: 32580620
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (1200 mg) + Faradic (three 1 hour sessions) + weight loss regime
Trial: 32580620
Drug: Placebo (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1200 mg) + weight loss regime
Trial: 33631337
Drug: Preoperative calcium
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative calcium and calcitriol supplementation (calcitriol 0.25 μg po bid and calcium carbonate 1,500 mg po tid 5 days preoperatively and continued postoperatively)
Trial: 34002565
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (vitamin E capsules, coenzyme Q10 capsules, Wuzi Yanzong pills)
Trial: 32692994
Drug: Blood arsenic
RxNorm normalized name: arsenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood arsenic levels less than 3.69 μg/L
Trial: 35186258
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate 3-monthly (PP3M)
Trial: 33535835
Drug: Fluzoparib (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluzoparib (120 mg) under fed conditions
Trial: 33535835
Drug: Fluzoparib (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluzoparib (120 mg) under fasted conditions
Trial: 32410362
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral MTX and OMP dexamethasone
Trial: 33904625
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g CG per day
Trial: 33904625
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g CG per day
Trial: 34625316
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (received the core and up to 4 custom elements of treatment, wrote what each image displayed)
Trial: 34063790
Drug: Minor allele
RxNorm normalized name: Vinca minor extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minor allele frequencies of SNPs associated with vitamin A metabolism
Trial: 35568683
Drug: LDL-C 190-219
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C 190-219 mg/dL
Trial: 35568683
Drug: LDL-C 220-249
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C 220-249 mg/dL
Trial: 35568683
Drug: LDL-C ≥300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C ≥300 mg/dL
Trial: 34176407
Drug: Baricitinib therapy
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baricitinib therapy
Trial: 34197452
Drug: Pharmaceutical and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical and healthy lifestyle interventions
Trial: 33749970
Drug: Ideal Body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ideal Body Weight (IBW) dosing
Trial: 33749970
Drug: Total Body
RxNorm normalized name: Total Body Massager Item
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Body Weight (TBW) dosing